Eli Lilly and Company (LLY)
775.12 USD -46.34 (-5.64%) Volume: 5.95M
Explore Eli Lilly and Company’s stock price, currently at 775.12 USD, which experienced a drop of -5.64% this trading session. Despite the recent decline, LLY shows a marginal YTD increase of +0.40%, with a notable trading volume of 5.95M. Analyze the resilience and potential growth of LLY stock in the pharmaceutical industry.
Latest developments on Eli Lilly and Company
Eli Lilly has been making significant moves in the pharmaceutical industry, with recent events leading to fluctuations in their stock price. The company recently licensed an early-stage ALS drug program from Alchemab in a $415 million pact, showing their commitment to advancing innovative treatments. Additionally, Eli Lilly broke ground on a $4.5 billion medicine foundry in Lebanon, demonstrating their dedication to bold scientific advancements. Despite some setbacks, such as a drop in stock price and missed earnings expectations, Eli Lilly remains a key player in the industry, with partnerships and strategic adjustments reinforcing their growth prospects.
A look at Eli Lilly and Company Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 3 | |
| Growth | 4 | |
| Resilience | 3 | |
| Momentum | 5 | |
| OVERALL SMART SCORE | 3.4 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
According to Smartkarma Smart Scores, Eli Lilly & Company has a positive long-term outlook based on its overall scores. With a high score in Momentum, the company is showing strong growth potential and market performance. Additionally, Eli Lilly scores well in Growth, indicating promising expansion opportunities in the pharmaceutical industry. Its Resilience score suggests a stable foundation for weathering market challenges, while the Dividend score reflects a moderate level of return for investors.
Eli Lilly & Company, a global pharmaceutical company, is positioned well for continued success in the industry. With a diverse product portfolio that includes pharmaceuticals for humans and animals sold worldwide, the company is well-established in various therapeutic areas such as neuroscience, oncology, and cardiovascular agents. The Smartkarma Smart Scores highlight Eli Lilly’s strengths in growth potential, market performance, and stability, making it a favorable choice for investors seeking long-term opportunities in the healthcare sector.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
